ID   M3K20_HUMAN             Reviewed;         800 AA.
AC   Q9NYL2; B3KPG2; Q53SX1; Q580W8; Q59GY5; Q86YW8; Q9HCC4; Q9HCC5; Q9HDD2;
AC   Q9NYE9;
DT   05-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 3.
DT   12-OCT-2022, entry version 190.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 20 {ECO:0000312|HGNC:HGNC:17797};
DE            EC=2.7.11.25;
DE   AltName: Full=Human cervical cancer suppressor gene 4 protein;
DE            Short=HCCS-4;
DE   AltName: Full=Leucine zipper- and sterile alpha motif-containing kinase;
DE   AltName: Full=MLK-like mitogen-activated protein triple kinase;
DE   AltName: Full=Mitogen-activated protein kinase kinase kinase MLT;
DE   AltName: Full=Mixed lineage kinase-related kinase;
DE            Short=MLK-related kinase;
DE            Short=MRK;
DE   AltName: Full=Sterile alpha motif- and leucine zipper-containing kinase AZK;
GN   Name=MAP3K20 {ECO:0000312|HGNC:HGNC:17797};
GN   Synonyms=MLTK, ZAK {ECO:0000303|PubMed:10924358}; ORFNames=HCCS4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAF63490.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   HOMODIMERIZATION, AND VARIANT LEU-531.
RC   TISSUE=Placenta {ECO:0000269|PubMed:10924358};
RX   PubMed=10924358; DOI=10.1006/bbrc.2000.3236;
RA   Liu T.-C., Huang C.-J., Chu Y.-C., Wei C.-C., Chou C.-C., Chou M.-Y.,
RA   Chou C.-K., Yang J.-J.;
RT   "Cloning and expression of ZAK, a mixed lineage kinase-like protein
RT   containing a leucine-zipper and a sterile-alpha motif.";
RL   Biochem. Biophys. Res. Commun. 274:811-816(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION (ISOFORM 1),
RP   PHOSPHORYLATION AT SER-429 (ISOFORM 2), AND VARIANT LEU-531.
RC   TISSUE=Fetal brain;
RX   PubMed=11042189; DOI=10.1074/jbc.m008595200;
RA   Gotoh I., Adachi M., Nishida E.;
RT   "Identification and characterization of a novel MAP kinase kinase kinase,
RT   MLTK.";
RL   J. Biol. Chem. 276:4276-4286(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Heart;
RX   PubMed=11549352; DOI=10.1006/jmcc.2001.1437;
RA   Bloem L.J., Pickard T.R., Acton S., Donoghue M., Beavis R.C.,
RA   Knierman M.D., Wang X.;
RT   "Tissue distribution and functional expression of a cDNA encoding a novel
RT   mixed lineage kinase.";
RL   J. Mol. Cell. Cardiol. 33:1739-1750(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE
RP   SPECIFICITY, MUTAGENESIS OF LYS-45, AND VARIANT LEU-531.
RC   TISSUE=T-cell {ECO:0000269|PubMed:11836244};
RX   PubMed=11836244; DOI=10.1074/jbc.m111994200;
RA   Gross E.A., Callow M.G., Waldbaum L., Thomas S., Ruggieri R.;
RT   "MRK, a mixed lineage kinase-related molecule that plays a role in gamma-
RT   radiation-induced cell cycle arrest.";
RL   J. Biol. Chem. 277:13873-13882(2002).
RN   [5] {ECO:0000305, ECO:0000312|EMBL:BAB12040.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lymphoid tissue;
RA   Abe Y., Ueda N.;
RT   "Placible mixed-lineage kinase derived from LAK cell.";
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6] {ECO:0000305, ECO:0000312|EMBL:BAB12040.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LEU-531.
RA   McNee J.J., Frima N., Diamond T.E., Dower S.K., Guesdon F.;
RT   "Cloning and characterisation of AZK, a mixed lineage kinase containing a
RT   sterile-alpha motif.";
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7] {ECO:0000305, ECO:0000312|EMBL:BAB12040.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Kim J.W.;
RT   "Identification of a new tumor suppressor in human cancers.";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9] {ECO:0000305, ECO:0000312|EMBL:BAB12040.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-784.
RC   TISSUE=Brain {ECO:0000312|EMBL:BAD92211.1};
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10] {ECO:0000312|EMBL:AAX82002.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [11] {ECO:0000305, ECO:0000312|EMBL:BAB12040.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12] {ECO:0000305, ECO:0000312|EMBL:AAH01401.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Colon {ECO:0000312|EMBL:AAH01401.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   INTERACTION WITH ZNF33A.
RX   PubMed=12535642; DOI=10.1016/s0006-291x(02)02980-7;
RA   Yang J.-J.;
RT   "A novel zinc finger protein, ZZaPK, interacts with ZAK and stimulates the
RT   ZAK-expressing cells re-entering the cell cycle.";
RL   Biochem. Biophys. Res. Commun. 301:71-77(2003).
RN   [14] {ECO:0000305}
RP   PHOSPHORYLATION, AND INTERACTION WITH PKN1.
RX   PubMed=12761180; DOI=10.1093/jb/mvg022;
RA   Takahashi M., Gotoh Y., Isagawa T., Nishimura T., Goyama E., Kim H.-S.,
RA   Mukai H., Ono Y.;
RT   "Regulation of a mitogen-activated protein kinase kinase kinase, MLTK by
RT   PKN.";
RL   J. Biochem. 133:181-187(2003).
RN   [15] {ECO:0000305}
RP   FUNCTION (ISOFORM 1).
RX   PubMed=15172994; DOI=10.1158/0008-5472.can-04-0201;
RA   Cho Y.-Y., Bode A.M., Mizuno H., Choi B.Y., Choi H.S., Dong Z.;
RT   "A novel role for mixed-lineage kinase-like mitogen-activated protein
RT   triple kinase alpha in neoplastic cell transformation and tumor
RT   development.";
RL   Cancer Res. 64:3855-3864(2004).
RN   [16] {ECO:0000305}
RP   FUNCTION IN DNA DAMAGE CHECKPOINTS, FUNCTION IN PHOSPHORYLATION OF CHEK2,
RP   ACTIVITY REGULATION, PHOSPHORYLATION AT THR-161 AND SER-165, AND
RP   MUTAGENESIS OF THR-161; THR-162 AND SER-165.
RX   PubMed=15342622; DOI=10.1074/jbc.m409961200;
RA   Tosti E., Waldbaum L., Warshaw G., Gross E.A., Ruggieri R.;
RT   "The stress kinase MRK contributes to regulation of DNA damage checkpoints
RT   through a p38gamma-independent pathway.";
RL   J. Biol. Chem. 279:47652-47660(2004).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF HISTONE H3 (ISOFORM 1), AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15684425; DOI=10.1074/jbc.m410521200;
RA   Choi H.S., Choi B.Y., Cho Y.-Y., Zhu F., Bode A.M., Dong Z.;
RT   "Phosphorylation of Ser28 in histone H3 mediated by mixed lineage kinase-
RT   like mitogen-activated protein triple kinase alpha.";
RL   J. Biol. Chem. 280:13545-13553(2005).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-275; SER-302; THR-628;
RP   SER-727 AND SER-733, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-339;
RP   SER-434 AND SER-454 (ISOFORM 2), AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-599; THR-628; SER-633;
RP   SER-727 AND SER-733, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-454
RP   (ISOFORM 2), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-275; THR-628; SER-633 AND SER-727, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-339; SER-434 AND SER-454 (ISOFORM 2), CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-633, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-727, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH AKAP13; PKN1; MAPK14 AND
RP   MAP2K3.
RX   PubMed=21224381; DOI=10.1074/jbc.m110.185645;
RA   Cariolato L., Cavin S., Diviani D.;
RT   "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling
RT   complex involved in alpha1-adrenergic receptor-induced p38 activation.";
RL   J. Biol. Chem. 286:7925-7937(2011).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567; SER-593; THR-628;
RP   SER-633; SER-637; SER-648; SER-649; SER-685; SER-727 AND SER-733, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-727, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [30]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-267; THR-281; VAL-281; LEU-531;
RP   TRP-580; THR-740; HIS-773 AND THR-784.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [31]
RP   INVOLVEMENT IN SFMMP, FUNCTION, SUBUNIT, VARIANT SFMMP CYS-368, AND
RP   CHARACTERIZATION OF VARIANT SFMMP CYS-368.
RX   PubMed=26755636; DOI=10.1101/gr.199430.115;
RA   Spielmann M., Kakar N., Tayebi N., Leettola C., Nuernberg G., Sowada N.,
RA   Lupianez D.G., Harabula I., Floettmann R., Horn D., Chan W.L., Wittler L.,
RA   Yilmaz R., Altmueller J., Thiele H., van Bokhoven H., Schwartz C.E.,
RA   Nuernberg P., Bowie J.U., Ahmad J., Kubisch C., Mundlos S., Borck G.;
RT   "Exome sequencing and CRISPR/Cas genome editing identify mutations of ZAK
RT   as a cause of limb defects in humans and mice.";
RL   Genome Res. 26:183-191(2016).
RN   [32]
RP   INVOLVEMENT IN CNM6, VARIANTS CNM6 95-ASN--PHE-800 DEL AND 172-TRP--PHE-800
RP   DEL, AND CHARACTERIZATION OF VARIANTS CNM6 95-ASN--PHE-800 DEL AND
RP   172-TRP--PHE-800 DEL.
RX   PubMed=27816943; DOI=10.1093/brain/aww257;
RA   Vasli N., Harris E., Karamchandani J., Bareke E., Majewski J., Romero N.B.,
RA   Stojkovic T., Barresi R., Tasfaout H., Charlton R., Malfatti E., Bohm J.,
RA   Marini-Bettolo C., Choquet K., Dicaire M.J., Shao Y.H., Topf A.,
RA   O'Ferrall E., Eymard B., Straub V., Blanco G., Lochmueller H., Brais B.,
RA   Laporte J., Tetreault M.;
RT   "Recessive mutations in the kinase ZAK cause a congenital myopathy with
RT   fibre type disproportion.";
RL   Brain 140:37-48(2017).
RN   [33]
RP   VARIANT CNM6 TRP-250.
RX   PubMed=30237576; DOI=10.1038/s41436-018-0138-x;
RA   Maddirevula S., Alzahrani F., Al-Owain M., Al Muhaizea M.A., Kayyali H.R.,
RA   AlHashem A., Rahbeeni Z., Al-Otaibi M., Alzaidan H.I., Balobaid A.,
RA   El Khashab H.Y., Bubshait D.K., Faden M., Yamani S.A., Dabbagh O.,
RA   Al-Mureikhi M., Jasser A.A., Alsaif H.S., Alluhaydan I., Seidahmed M.Z.,
RA   Alabbasi B.H., Almogarri I., Kurdi W., Akleh H., Qari A., Al Tala S.M.,
RA   Alhomaidi S., Kentab A.Y., Salih M.A., Chedrawi A., Alameer S., Tabarki B.,
RA   Shamseldin H.E., Patel N., Ibrahim N., Abdulwahab F., Samira M., Goljan E.,
RA   Abouelhoda M., Meyer B.F., Hashem M., Shaheen R., AlShahwan S.,
RA   Alfadhel M., Ben-Omran T., Al-Qattan M.M., Monies D., Alkuraya F.S.;
RT   "Autozygome and high throughput confirmation of disease genes candidacy.";
RL   Genet. Med. 21:736-742(2019).
CC   -!- FUNCTION: Stress-activated component of a protein kinase signal
CC       transduction cascade. Regulates the JNK and p38 pathways. Part of a
CC       signaling cascade that begins with the activation of the adrenergic
CC       receptor ADRA1B and leads to the activation of MAPK14. Pro-apoptotic.
CC       Role in regulation of S and G2 cell cycle checkpoint by direct
CC       phosphorylation of CHEK2 (PubMed:10924358, PubMed:11836244,
CC       PubMed:15342622, PubMed:21224381). Involved in limb development
CC       (PubMed:26755636). {ECO:0000269|PubMed:10924358,
CC       ECO:0000269|PubMed:11836244, ECO:0000269|PubMed:15342622,
CC       ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.
CC   -!- FUNCTION: [Isoform 1]: Phosphorylates histone H3 at 'Ser-28'
CC       (PubMed:15684425). May have role in neoplastic cell transformation and
CC       cancer development (PubMed:15172994). Causes cell shrinkage and
CC       disruption of actin stress fibers (PubMed:11042189).
CC       {ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:15172994,
CC       ECO:0000269|PubMed:15684425}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25;
CC         Evidence={ECO:0000269|PubMed:11836244};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.25; Evidence={ECO:0000269|PubMed:11836244};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:11836244};
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation by PKN1 and
CC       autophosphorylation on Thr-161 and Ser-165.
CC       {ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:12761180,
CC       ECO:0000269|PubMed:15342622}.
CC   -!- SUBUNIT: Homodimer (PubMed:10924358, PubMed:26755636). Interacts with
CC       PKN1 and ZNF33A (PubMed:12535642, PubMed:12761180). Component of a
CC       signaling complex containing at least AKAP13, PKN1, MAPK14, MAP3K20 and
CC       MAP2K3. Within this complex, AKAP13 interacts directly with PKN1, which
CC       in turn recruits MAPK14, MAP2K3 and MAP3K20 (PubMed:21224381).
CC       {ECO:0000269|PubMed:10924358, ECO:0000269|PubMed:12535642,
CC       ECO:0000269|PubMed:12761180, ECO:0000269|PubMed:21224381,
CC       ECO:0000269|PubMed:26755636}.
CC   -!- INTERACTION:
CC       Q9NYL2; O75582: RPS6KA5; NbExp=4; IntAct=EBI-602273, EBI-73869;
CC       Q9NYL2; P63104: YWHAZ; NbExp=5; IntAct=EBI-602273, EBI-347088;
CC       Q9NYL2; Q8N184: ZNF567; NbExp=3; IntAct=EBI-602273, EBI-749400;
CC       Q9NYL2-1; Q16512: PKN1; NbExp=2; IntAct=EBI-687346, EBI-602382;
CC       Q9NYL2-2; Q6P2D0: ZFP1; NbExp=4; IntAct=EBI-10255081, EBI-2555749;
CC       Q9NYL2-2; Q6ZN57: ZFP2; NbExp=7; IntAct=EBI-10255081, EBI-7236323;
CC       Q9NYL2-2; P13682: ZNF35; NbExp=3; IntAct=EBI-10255081, EBI-11041653;
CC       Q9NYL2-2; Q8N184: ZNF567; NbExp=7; IntAct=EBI-10255081, EBI-749400;
CC       Q9NYL2-2; Q6AZW8: ZNF660; NbExp=3; IntAct=EBI-10255081, EBI-12376497;
CC       Q9NYL2-2; Q9NQZ8: ZNF71; NbExp=4; IntAct=EBI-10255081, EBI-7138235;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15684425}. Nucleus
CC       {ECO:0000269|PubMed:15684425}. Note=Translocates to the nucleus upon
CC       ultraviolet B irradiation. {ECO:0000269|PubMed:15684425}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1 {ECO:0000269|PubMed:11042189}; Synonyms=Alpha;
CC         IsoId=Q9NYL2-1; Sequence=Displayed;
CC       Name=2 {ECO:0000269|PubMed:11042189}; Synonyms=Beta;
CC         IsoId=Q9NYL2-2; Sequence=VSP_051743, VSP_051744;
CC       Name=3; Synonyms=HCCS-4;
CC         IsoId=Q9NYL2-3; Sequence=VSP_051741, VSP_051742;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is the
CC       predominant form in all tissues examined, except for liver, in which
CC       isoform 1 is more highly expressed. {ECO:0000269|PubMed:10924358,
CC       ECO:0000269|PubMed:11836244}.
CC   -!- DISEASE: Split-foot malformation with mesoaxial polydactyly (SFMMP)
CC       [MIM:616890]: An autosomal recessive disorder characterized by a split-
CC       foot defect, mesoaxial polydactyly, nail abnormalities of the hands,
CC       and sensorineural hearing loss. {ECO:0000269|PubMed:26755636}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Myopathy, centronuclear, 6, with fiber-type disproportion
CC       (CNM6) [MIM:617760]: A form of centronuclear myopathy, a congenital
CC       muscle disorder characterized by progressive muscular weakness and
CC       wasting involving mainly limb girdle, trunk, and neck muscles. It may
CC       also affect distal muscles. Weakness may be present during childhood or
CC       adolescence or may not become evident until the third decade of life.
CC       Ptosis is a frequent clinical feature. The most prominent
CC       histopathologic features include high frequency of centrally located
CC       nuclei in muscle fibers not secondary to regeneration, radial
CC       arrangement of sarcoplasmic strands around the central nuclei, and
CC       predominance and hypotrophy of type 1 fibers. CNM6 is an autosomal
CC       recessive, slowly progressive form with onset in infancy or early
CC       childhood. {ECO:0000269|PubMed:27816943, ECO:0000269|PubMed:30237576}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92211.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF238255; AAF63490.1; -; mRNA.
DR   EMBL; AB049733; BAB16444.1; -; mRNA.
DR   EMBL; AB049734; BAB16445.1; -; mRNA.
DR   EMBL; AF325454; AAK11615.1; -; mRNA.
DR   EMBL; AF480461; AAL85891.1; -; mRNA.
DR   EMBL; AF480462; AAL85892.1; -; mRNA.
DR   EMBL; AB030034; BAB12040.1; -; mRNA.
DR   EMBL; AF251441; AAF65822.1; -; mRNA.
DR   EMBL; AF465843; AAO33376.1; -; mRNA.
DR   EMBL; AK056310; BAG51674.1; -; mRNA.
DR   EMBL; AB208974; BAD92211.1; ALT_INIT; mRNA.
DR   EMBL; AC092573; AAX82002.1; -; Genomic_DNA.
DR   EMBL; AC013461; AAX93067.1; -; Genomic_DNA.
DR   EMBL; AC019046; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471058; EAX11164.1; -; Genomic_DNA.
DR   EMBL; BC001401; AAH01401.1; -; mRNA.
DR   CCDS; CCDS2251.1; -. [Q9NYL2-2]
DR   CCDS; CCDS42777.1; -. [Q9NYL2-1]
DR   RefSeq; NP_057737.2; NM_016653.2. [Q9NYL2-1]
DR   RefSeq; NP_598407.1; NM_133646.2. [Q9NYL2-2]
DR   RefSeq; XP_005246697.1; XM_005246640.2. [Q9NYL2-1]
DR   RefSeq; XP_016859812.1; XM_017004323.1. [Q9NYL2-2]
DR   RefSeq; XP_016859813.1; XM_017004324.1. [Q9NYL2-2]
DR   PDB; 5HES; X-ray; 2.14 A; A/B=5-309.
DR   PDB; 5X5O; X-ray; 1.87 A; A=5-309.
DR   PDB; 6JUT; X-ray; 2.10 A; A=5-309.
DR   PDB; 6JUU; X-ray; 1.90 A; A=5-309.
DR   PDBsum; 5HES; -.
DR   PDBsum; 5X5O; -.
DR   PDBsum; 6JUT; -.
DR   PDBsum; 6JUU; -.
DR   AlphaFoldDB; Q9NYL2; -.
DR   SMR; Q9NYL2; -.
DR   BioGRID; 119725; 92.
DR   CORUM; Q9NYL2; -.
DR   IntAct; Q9NYL2; 48.
DR   MINT; Q9NYL2; -.
DR   STRING; 9606.ENSP00000364361; -.
DR   BindingDB; Q9NYL2; -.
DR   ChEMBL; CHEMBL3886; -.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9NYL2; -.
DR   GuidetoPHARMACOLOGY; 2289; -.
DR   iPTMnet; Q9NYL2; -.
DR   MetOSite; Q9NYL2; -.
DR   PhosphoSitePlus; Q9NYL2; -.
DR   BioMuta; MAP3K20; -.
DR   DMDM; 313104215; -.
DR   EPD; Q9NYL2; -.
DR   jPOST; Q9NYL2; -.
DR   MassIVE; Q9NYL2; -.
DR   MaxQB; Q9NYL2; -.
DR   PaxDb; Q9NYL2; -.
DR   PeptideAtlas; Q9NYL2; -.
DR   PRIDE; Q9NYL2; -.
DR   ProteomicsDB; 83246; -. [Q9NYL2-1]
DR   ProteomicsDB; 83248; -. [Q9NYL2-3]
DR   Antibodypedia; 2065; 318 antibodies from 33 providers.
DR   DNASU; 51776; -.
DR   Ensembl; ENST00000338983.7; ENSP00000340257.3; ENSG00000091436.17. [Q9NYL2-2]
DR   Ensembl; ENST00000375213.8; ENSP00000364361.3; ENSG00000091436.17. [Q9NYL2-1]
DR   Ensembl; ENST00000409176.6; ENSP00000387259.2; ENSG00000091436.17. [Q9NYL2-1]
DR   Ensembl; ENST00000539448.5; ENSP00000439414.1; ENSG00000091436.17. [Q9NYL2-2]
DR   GeneID; 51776; -.
DR   KEGG; hsa:51776; -.
DR   MANE-Select; ENST00000375213.8; ENSP00000364361.3; NM_016653.3; NP_057737.2.
DR   UCSC; uc002uhz.4; human. [Q9NYL2-1]
DR   CTD; 51776; -.
DR   DisGeNET; 51776; -.
DR   GeneCards; MAP3K20; -.
DR   HGNC; HGNC:17797; MAP3K20.
DR   HPA; ENSG00000091436; Tissue enhanced (skeletal muscle, tongue).
DR   MalaCards; MAP3K20; -.
DR   MIM; 609479; gene.
DR   MIM; 616890; phenotype.
DR   MIM; 617760; phenotype.
DR   neXtProt; NX_Q9NYL2; -.
DR   OpenTargets; ENSG00000091436; -.
DR   Orphanet; 2020; Congenital fiber-type disproportion myopathy.
DR   Orphanet; 488232; Split-foot malformation-mesoaxial polydactyly syndrome.
DR   VEuPathDB; HostDB:ENSG00000091436; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   GeneTree; ENSGT00940000161352; -.
DR   HOGENOM; CLU_019131_1_0_1; -.
DR   InParanoid; Q9NYL2; -.
DR   OMA; QSNTPFF; -.
DR   OrthoDB; 938929at2759; -.
DR   PhylomeDB; Q9NYL2; -.
DR   PathwayCommons; Q9NYL2; -.
DR   SignaLink; Q9NYL2; -.
DR   SIGNOR; Q9NYL2; -.
DR   BioGRID-ORCS; 51776; 10 hits in 1062 CRISPR screens.
DR   ChiTaRS; MAP3K20; human.
DR   GeneWiki; ZAK; -.
DR   GenomeRNAi; 51776; -.
DR   Pharos; Q9NYL2; Tchem.
DR   PRO; PR:Q9NYL2; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9NYL2; protein.
DR   Bgee; ENSG00000091436; Expressed in heart right ventricle and 190 other tissues.
DR   ExpressionAtlas; Q9NYL2; baseline and differential.
DR   Genevisible; Q9NYL2; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0004706; F:JUN kinase kinase kinase activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0008219; P:cell death; NAS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; NAS:UniProtKB.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IDA:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0000077; P:DNA damage checkpoint signaling; IMP:UniProtKB.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IMP:UniProtKB.
DR   GO; GO:0007254; P:JNK cascade; IDA:UniProtKB.
DR   GO; GO:0060173; P:limb development; IMP:UniProtKB.
DR   GO; GO:0038066; P:p38MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:1904291; P:positive regulation of mitotic DNA damage checkpoint; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IDA:UniProtKB.
DR   Gene3D; 1.10.150.50; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00454; SAM; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle;
KW   Cytoplasm; Disease variant; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:22223895"
FT   CHAIN           2..800
FT                   /note="Mitogen-activated protein kinase kinase kinase 20"
FT                   /id="PRO_0000086338"
FT   DOMAIN          16..277
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          339..410
FT                   /note="SAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00184"
FT   REGION          287..308
FT                   /note="Leucine-zipper"
FT   REGION          652..800
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        652..668
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        680..707
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        752..800
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        133
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:P80192,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE-
FT                   ProRule:PRU10027"
FT   BINDING         22..30
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P80192,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         45
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:11836244"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:22223895"
FT   MOD_RES         161
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15342622"
FT   MOD_RES         165
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15342622"
FT   MOD_RES         275
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         302
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         567
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         593
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         599
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         628
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         633
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         637
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         648
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         649
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         685
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         727
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         733
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         285..312
FT                   /note="CEIEATLERLKKLERDLSFKEQELKERE -> WVAPTAGHSVWLSKTITRLN
FT                   EEVNQRSE (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_051741"
FT   VAR_SEQ         313..800
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_051742"
FT   VAR_SEQ         332..455
FT                   /note="PSFEIGAWTEDDVYCWVQQLVRKGDSSAEMSVYASLFKENNITGKRLLLLEE
FT                   EDLKDMGIVSKGHIIHFKSAIEKLTHDYINLFHFPPLIKDSGGEPEENEEKIVNLELVF
FT                   GFHLKPGTGPQDC -> LPLAARMSEESYFESKTEESNSAEMSCQITATSNGEGHGMNP
FT                   SLQAMMLMGFGDIFSMNKAGAVMHSGMQINMQAKQNSSKTTSKRRGKKVNMALGFSDFD
FT                   LSEGDDDDDDDGEEEDNDMDNSE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11042189,
FT                   ECO:0000303|PubMed:11549352, ECO:0000303|PubMed:11836244,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_051743"
FT   VAR_SEQ         456..800
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11042189,
FT                   ECO:0000303|PubMed:11549352, ECO:0000303|PubMed:11836244,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_051744"
FT   VARIANT         95..800
FT                   /note="Missing (in CNM6; decrease of protein abundance)"
FT                   /evidence="ECO:0000269|PubMed:27816943"
FT                   /id="VAR_080563"
FT   VARIANT         172..800
FT                   /note="Missing (in CNM6; decrease of protein abundance)"
FT                   /evidence="ECO:0000269|PubMed:27816943"
FT                   /id="VAR_080564"
FT   VARIANT         250
FT                   /note="R -> W (in CNM6; unknown pathological significance;
FT                   dbSNP:rs763481300)"
FT                   /evidence="ECO:0000269|PubMed:30237576"
FT                   /id="VAR_082158"
FT   VARIANT         267
FT                   /note="T -> M (in dbSNP:rs6758025)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040806"
FT   VARIANT         281
FT                   /note="A -> T (in an ovarian endometrioid sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040807"
FT   VARIANT         281
FT                   /note="A -> V (in dbSNP:rs34683477)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040808"
FT   VARIANT         368
FT                   /note="F -> C (in SFMMP; produces protein aggregation;
FT                   dbSNP:rs863225437)"
FT                   /evidence="ECO:0000269|PubMed:26755636"
FT                   /id="VAR_076448"
FT   VARIANT         531
FT                   /note="S -> L (in dbSNP:rs3769148)"
FT                   /evidence="ECO:0000269|PubMed:10924358,
FT                   ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:11836244,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|Ref.6"
FT                   /id="VAR_022827"
FT   VARIANT         580
FT                   /note="R -> W (in dbSNP:rs7593622)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040809"
FT   VARIANT         740
FT                   /note="P -> T (in dbSNP:rs56202258)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040810"
FT   VARIANT         773
FT                   /note="Y -> H (in dbSNP:rs35608243)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040811"
FT   VARIANT         784
FT                   /note="K -> T (in dbSNP:rs55830025)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.9"
FT                   /id="VAR_040812"
FT   MUTAGEN         45
FT                   /note="K->M: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:11836244"
FT   MUTAGEN         161
FT                   /note="T->A: Loss of autophosphorylation activity."
FT                   /evidence="ECO:0000269|PubMed:15342622"
FT   MUTAGEN         162
FT                   /note="T->A: Slight loss of autophosphorylation activity."
FT                   /evidence="ECO:0000269|PubMed:15342622"
FT   MUTAGEN         165
FT                   /note="S->A: Loss of autophosphorylation activity."
FT                   /evidence="ECO:0000269|PubMed:15342622"
FT   CONFLICT        346
FT                   /note="C -> W (in Ref. 1; AAF63490)"
FT                   /evidence="ECO:0000305"
FT   HELIX           13..15
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   STRAND          16..20
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   STRAND          24..26
FT                   /evidence="ECO:0007829|PDB:6JUT"
FT   STRAND          30..35
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   TURN            36..39
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   STRAND          40..48
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           52..57
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   STRAND          68..74
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   STRAND          77..83
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           90..94
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           97..101
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           104..123
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   STRAND          125..127
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           136..138
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   STRAND          139..141
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   STRAND          147..149
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           154..157
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           159..162
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           163..166
FT                   /evidence="ECO:0007829|PDB:6JUT"
FT   TURN            167..169
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           170..172
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           175..178
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           186..201
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   TURN            205..208
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           211..220
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           233..242
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           247..249
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           253..264
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           269..277
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   HELIX           280..298
FT                   /evidence="ECO:0007829|PDB:5X5O"
FT   MOD_RES         Q9NYL2-2:339
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         Q9NYL2-2:429
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11042189"
FT   MOD_RES         Q9NYL2-2:434
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         Q9NYL2-2:454
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195"
SQ   SEQUENCE   800 AA;  91155 MW;  B2814509EC54B07A CRC64;
     MSSLGASFVQ IKFDDLQFFE NCGGGSFGSV YRAKWISQDK EVAVKKLLKI EKEAEILSVL
     SHRNIIQFYG VILEPPNYGI VTEYASLGSL YDYINSNRSE EMDMDHIMTW ATDVAKGMHY
     LHMEAPVKVI HRDLKSRNVV IAADGVLKIC DFGASRFHNH TTHMSLVGTF PWMAPEVIQS
     LPVSETCDTY SYGVVLWEML TREVPFKGLE GLQVAWLVVE KNERLTIPSS CPRSFAELLH
     QCWEADAKKR PSFKQIISIL ESMSNDTSLP DKCNSFLHNK AEWRCEIEAT LERLKKLERD
     LSFKEQELKE RERRLKMWEQ KLTEQSNTPL LPSFEIGAWT EDDVYCWVQQ LVRKGDSSAE
     MSVYASLFKE NNITGKRLLL LEEEDLKDMG IVSKGHIIHF KSAIEKLTHD YINLFHFPPL
     IKDSGGEPEE NEEKIVNLEL VFGFHLKPGT GPQDCKWKMY MEMDGDEIAI TYIKDVTFNT
     NLPDAEILKM TKPPFVMEKW IVGIAKSQTV ECTVTYESDV RTPKSTKHVH SIQWSRTKPQ
     DEVKAVQLAI QTLFTNSDGN PGSRSDSSAD CQWLDTLRMR QIASNTSLQR SQSNPILGSP
     FFSHFDGQDS YAAAVRRPQV PIKYQQITPV NQSRSSSPTQ YGLTKNFSSL HLNSRDSGFS
     SGNTDTSSER GRYSDRSRNK YGRGSISLNS SPRGRYSGKS QHSTPSRGRY PGKFYRVSQS
     ALNPHQSPDF KRSPRDLHQP NTIPGMPLHP ETDSRASEED SKVSEGGWTK VEYRKKPHRP
     SPAKTNKERA RGDHRGWRNF
//
